This is a continuation of a long topic, addressed by post number rather than by page. Start at post 1.
Everything in post #119 holds. The case it does not cover is the one I have.
Escalating before steady state means you are judging a dose you have not yet fully experienced. That is the whole argument against compressing the schedule and it is a good one.
Adding it because I spent an afternoon working it out and nobody should have to twice.
Holding at a dose that is working is a legitimate position and it is not what the trial protocols did. The protocols escalated to a target because they were measuring the target dose, not finding each person's minimum.
No disagreement from me. Posting only so the question does not look ignored.
Posting my Splitting a weekly dose numbers with the method attached so they can be discounted properly. Uncontrolled, unblinded, and collected by someone who wanted a particular answer.
Answering the question post #124 raises rather than the one it answers.
Dose and effect are not linear across the studied range for every compound in this class. Assuming a doubled dose gives a doubled effect is the reasoning error behind most disappointment.
The answer changed when I changed how I was measuring, which was informative.
The arithmetic in post #124 is right; the assumption feeding it is the part to check.
Going back down a step is not a failure and the trials allowed it. Several protocols permitted a return to the previous dose for tolerability and then a second attempt at the step.
One more caveat and then I will stop qualifying: the sample selected itself.
The arithmetic of an intermediate dose: if the label says 1.0 mg and 2.0 mg, a dose strictly between them is off-label by definition. Some people compute it anyway. The reasoning is pharmacological — e.g., "I will split the difference between steps" — but it is reasoning from theory, not from evidence.
Dose equivalence between different incretin analogues is a weak concept. The molecules differ in structure, half-life, receptor selectivity, and in what has been studied clinically. One mg of semaglutide is not equivalent to one mg of something else in any meaningful sense.
The maximum studied dose is a fact about the trial and not a ceiling on the molecule. It is also the last point at which anything is known, which is the reason to treat it as one.
Adding the caveat now so it does not have to be extracted later.
Adding the measurement that post #127 says would settle it.
The four-week step is a trial convention, not a pharmacological constant. It is roughly four half-lives for a week-long half-life, which is the interval at which you are assessing a stable concentration rather than a rising one.
That is the shape of it. The detail is where I would expect to be corrected.
Post #128 and I disagree about the size of the effect, not about the direction.
Writing down the date, the dose and the site each week takes fifteen seconds and is the single most useful record anyone here keeps. Memory reconstructs a titration history that never happened.
Same conclusion as the reply above, reached differently, which is mildly reassuring.
Dose and effect are not linear across the studied range for every compound in this class. Assuming a doubled dose gives a doubled effect is the reasoning error behind most disappointment.
Not the answer, but possibly the question that gets there.
This follows post #132 rather than contradicting it.
A missed dose in a weekly schedule is not a trough to chase. With a week-long half-life you are perturbing a slowly moving average, and the labelling for licensed products in this class says take it if the next dose is far enough away and skip it otherwise.
That has been true for the cases I have seen and I have not seen many.
Worth separating two things that post #132 runs together.
If symptoms reset at each step, that is the expected pattern rather than a sign that the previous adaptation was imaginary. Every dose increase is a new exposure.
I have changed my mind on this once already, so take it as current rather than settled.
Holding at a dose that is working is a legitimate position and it is not what the trial protocols did. The protocols escalated to a target because they were measuring the target dose, not finding each person's minimum.
The evidence for this is thinner than the way I have phrased it suggests.
Picking up post #138: that is the part I would want checked first.
Reframing Splitting a weekly dose slightly, because I think the disagreement is about the question rather than the answer. If the question is "does it happen", yes. If it is "how often", nobody here knows.
That is the distinction I keep failing to hold on to. Written down now.
If you are stepping up mainly because the schedule says so rather than because the current dose has stopped doing what you wanted, that is worth noticing before rather than afterwards.
Post #141 describes the usual case. This is about the unusual one.
Doubling after a miss adds a peak for no gain and is not what any labelling in this class recommends. That is a description of the labelling rather than advice about anyone's situation.
That is the version I would defend. It is not the version I started with.
Adding the measurement that post #141 says would settle it.
The four-week escalation interval is a convention from the pivotal trials, not a pharmacological constant. The pharmacological argument is that with a week-long half-life, four weeks approaches steady state and you can assess the dose fairly. That is an argument for not going faster. It is not an argument against going slower.
I have deliberately not rounded that, because the rounding is where the argument starts.
Where I part company with post #141, and it is a narrow parting.
Small correction to my own earlier position on Splitting a weekly dose. I had the units the wrong way round, which changes the conclusion by an order of magnitude and therefore changes it entirely.
Worth separating Splitting a weekly dose as a question about the compound from Splitting a weekly dose as a question about the documentation. They get answered by different people and only one of them is answerable here.
Steady state means the plasma concentration is stable from dose to dose. That happens around 4 to 5 half-lives. Before that, the concentration is rising with each dose. Escalating before steady state means escalating on incomplete information about the dose you are on.
A qualification I should have led with rather than closed on.
The arithmetic in post #145 is right; the assumption feeding it is the part to check.
Holding a dose indefinitely: the trials did not study indefinite holding at a non-maximum dose. The trials escalated to a target and then held that. What happens if you stay at an intermediate dose for years is not formally studied and extrapolation is the best available reasoning.
The rule of thumb is fine; the edge cases are where it earns its keep.
I read post #145 twice before replying, because I had assumed the opposite.
The starting dose in most of these programmes is a tolerance step and produces little effect by design. Judging the compound at the starting dose is judging the wrong thing.
If this contradicts something upthread, the upthread version may well be the better one.
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Where the four-week escalation interval comes from, and what it is not
On the subject in the title: Where the four-week escalation interval comes from, and what it is not Working notes rather than a conclusion. Working notes on four-week escalation interval rather than a…
|
+56 | 60 | 21k | 2y |
|
About the Dosing & titration category
Schedules, escalation intervals, dose reductions, and the arithmetic that connects a vial to a syringe mark. This post is a community wiki: any member at trust level 3 or above can edit it, and every edit is…
|
4 | 350 | 4mo | |
|
Restarting after a long gap: what the labelling implies — the long version
Restarting after a long gap: what the labelling implies — the long version Writing it up because I had to work it out twice and would rather nobody else did. I have read the maintained page on this and I…
|
+12 | 17 | 2.4k | 2mo |
|
How the published trials escalated, tabulated side by side — does this still hold?
Asking directly, because I could not find a straight answer: How the published trials escalated, tabulated side by side — does this still hold? Asking about published trials escalated directly, because I have…
|
2 | 8.9k | 9mo | |
|
[2026 update] What steady state means for the decision to escalate
The question in the title: What steady state means for the decision to escalate I will give what I have already checked below so nobody repeats it. Asking about steady state directly, because I have read four…
|
+127 | 137 | 32k | 8mo |
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
GLP-1 receptor distribution: central and peripheral
Posting this under the heading it deserves: GLP-1 receptor distribution: central and peripheral Everything below is what sits behind that. I have spent a fortnight trying to pin GLP-1 receptor distribution…
|
+90 | 98 | 30k | 22h |
|
Comparing the STEP programme populations: who was actually enrolled
Comparing the STEP programme populations: who was actually enrolled Writing it up because I had to work it out twice and would rather nobody else did. Two things I would like separated before anyone answers…
|
2 | 7.5k | 2mo | |
|
Micro-titration: a disputed topic, argued properly
Micro-titration: a disputed topic, argued properly Writing it up because I had to work it out twice and would rather nobody else did. Two things I would like separated before anyone answers on…
|
+99 | 110 | 61k | 2d |
|
How the published trials escalated, tabulated side by side — does this still hold?
Asking directly, because I could not find a straight answer: How the published trials escalated, tabulated side by side — does this still hold? Asking about published trials escalated directly, because I have…
|
2 | 8.9k | 9mo | |
|
Coming back to: Half-life, steady state, and accumulation worked through
On the subject in the title: Half-life, steady state, and accumulation worked through Working notes rather than a conclusion. Working through the kinetics rather than the pharmacology, because I think the…
|
+14 | 18 | 15k | 3mo |